Milestone Pharmaceuticals (MIST) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Milestone Pharmaceuticals has announced its second quarter financial results, revealing a cash reserve sufficient to fund operations through 2026 and the FDA’s acceptance of their new drug, CARDAMYST™, for PSVT, with a potential launch in 2025. Additionally, preparations for a Phase 3 study in AFib-RVR are underway, reflecting the company’s ongoing strategic advancements in its drug development pipeline.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
